Introduction: Colorectal cancer (CRC) screening programs based on the fecal immunochemical test (FIT) and guaiac-based fecal occult blood (gFOBT) are associated with a substantial reduction in CRC incidence and mortality. We conducted a systematic review and comprehensive meta-analysis to evaluate colonoscopy related adverse events in individuals with a positive FIT or gFOBT. Methods: A systematic and detailed search was run in January 2021 with the assistance of a medical librarian for studies reporting on colonoscopy related adverse events as part of organized colorectal cancer screening programs. Meta-analysis was performed using random-effects model and results were expressed in terms of pooled proportions along with relevant 95% confidence intervals (CI). Results: A total of 771,730 colonoscopies were performed in patients undergoing CRC screening using either gFOBT or FIT across 31 studies. Overall pooled incidence of severe adverse events in the entire patient cohort was 0.42% (CI 0.20-0.64); I2=38.76%. In patients with abnormal gFOBT, the incidence was 0.2% (CI 0.1-0.3); I2=24.6% and in patients with a positive FIT, it was 0.4% (CI 0.2-0.7); I2=48.89%. The overall pooled incidence of perforation, bleeding and death was 0.13% (CI 0.09-0.21); I2=22.84%, 0.3% (CI 0.2-0.4); I2=35.58% and 0.01% (CI 0.00-0.01); I2=33.21%, respectively. Discussion: Our analysis shows that in colonoscopies performed following abnormal stool-based testing, the overall risk of severe adverse events, perforation, bleeding, and death is minimal.
Colonoscopy related adverse events in patients with abnormal stool-based tests - A systematic review of literature and meta-analysis of outcomes
Facciorusso, Antonio;
2021-01-01
Abstract
Introduction: Colorectal cancer (CRC) screening programs based on the fecal immunochemical test (FIT) and guaiac-based fecal occult blood (gFOBT) are associated with a substantial reduction in CRC incidence and mortality. We conducted a systematic review and comprehensive meta-analysis to evaluate colonoscopy related adverse events in individuals with a positive FIT or gFOBT. Methods: A systematic and detailed search was run in January 2021 with the assistance of a medical librarian for studies reporting on colonoscopy related adverse events as part of organized colorectal cancer screening programs. Meta-analysis was performed using random-effects model and results were expressed in terms of pooled proportions along with relevant 95% confidence intervals (CI). Results: A total of 771,730 colonoscopies were performed in patients undergoing CRC screening using either gFOBT or FIT across 31 studies. Overall pooled incidence of severe adverse events in the entire patient cohort was 0.42% (CI 0.20-0.64); I2=38.76%. In patients with abnormal gFOBT, the incidence was 0.2% (CI 0.1-0.3); I2=24.6% and in patients with a positive FIT, it was 0.4% (CI 0.2-0.7); I2=48.89%. The overall pooled incidence of perforation, bleeding and death was 0.13% (CI 0.09-0.21); I2=22.84%, 0.3% (CI 0.2-0.4); I2=35.58% and 0.01% (CI 0.00-0.01); I2=33.21%, respectively. Discussion: Our analysis shows that in colonoscopies performed following abnormal stool-based testing, the overall risk of severe adverse events, perforation, bleeding, and death is minimal.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
